Key result
Guideline-compliant therapy for community-acquired pneumonia significantly reduced the risk of first-line therapy failure compared to noncompliant therapies (OR 0.74; 95% CI 0.60-0.90).
Why the study?
Does adherence to Italian guidelines reduce failure rate and mortality in hospitalised community-acquired pneumonia patients?
Does adherence to Italian guidelines reduce failure rate and mortality in hospitalised community-acquired pneumonia patients?
Odds Ratio: 0.74 (95% CI 0.6–0.9)
Adherence to CAP guidelines in internal medicine departments is associated with lower rates of first-line therapy failure and mortality, though overall compliance remains low.
May support efforts to boost CAP guideline adherence; leaves open need for RCTs to confirm causality.
The impact of compliance with Italian guidelines on the outcome of hospitalised community-acquired pneumonia (CAP) in internal medicine departments was evaluated. All Fine class IV or V CAP patients were included in this multicentre, interventional, before-and-after study, composed of three phases: 1) a retrospective phase (RP; 1,443 patients); 2) a guideline implementation phase; and 3) a prospective phase (PP; 1,404 patients). Antibiotic prescription according to the guidelines increased significantly in the PP. The risk of failure at the end of the firstline therapy was significantly lower in the PP versus the RP (odds ratio (OR) 0.83, 95% confidence interval (CI) 0.69-1.00), particularly in Fine class V patients (OR 0.71, 95% CI 0.51-0.98). Analysis of outcome in the overall population (2,847 patients) showed a statistically significant advantage for compliant versus noncompliant therapies in terms of failure rate (OR 0.74, 95% CI 0.60-0.90) and an advantage in terms of mortality (OR 0.77, 95% CI 0.58-1.04). Antipneumococcal cephalosporin monotherapy was associated with a low success rate (68.6%) and the highest mortality (16.2%); levofloxacin alone and the combination of cephalosporin and macrolide resulted in higher success rates (79.1 and 76.7%, respectively) and significantly lower mortalities (9.1 and 5.7%, respectively). Overall, a low compliance with guidelines in the prospective phase (44%) was obtained, indicating the need for future more aggressive and proactive approaches.
No takes yet. Share an insight, caveat, or question.
Blasi et al. (2008) studied Community-acquired pneumonia (CAP) (n=2,847). Guideline-compliant antibiotic therapy vs. Noncompliant therapy / Retrospective phase was evaluated on Failure rate at the end of firstline therapy (OR 0.74, 95% CI 0.60-0.90). Guideline-compliant therapy for community-acquired pneumonia significantly reduced the risk of first-line therapy failure compared to noncompliant therapies (OR 0.74; 95% CI 0.60-0.90).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: